Sage Journals: Discover world-class research

Open access

Review article

First published 2023

Precision oncology with selective RET inhibitor selpercatinib in RET -rearranged cancers

Mohamed A. Gouda, Vivek Subbiah

Therapeutic Advances in Medical Oncology

Retricted access

Review article

First published 2023-3

An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)

Vanessa Quang Nguyen, Marc Geirnaert

Journal of Oncology Pharmacy Practice

Retricted access

Case report

First published 2025-12

Selpercatinib plus cemiplimab in RET positive medullary thyroid cancer patient with skin cancers

Laura Deborah Locati, Federica Puce, Vito Amoroso [...]

Tumori Journal

Retricted access

Research article

First published 2023-03-16

A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion

Ayanthi Wijewardene, Karine Bastard, Bin Wang [...]

VideoEndocrinology™

Retricted access

Case report

First published 2026

Central nervous system effectiveness of selpercatinib retreatment in heavily pretreated NSCLC patient with RET rearrangement: A case report

Margherita Agostini, Samuele Compagno, Francesca Sperandi [...]

Tumori Journal

Retricted access

Research article

First published 2022-06-28

Response to Selpercatinib in an Adolescent with RET Fusion-Positive Papillary Thyroid Carcinoma with Extensive Intracranial and Pulmonary Metastases

Priya Mahajan, Rajkumar Venkatramani

VideoEndocrinology™

Open access

Research article

First published 2022

Efficacy and safety of selpercatinib in Chinese patients with advanced RET -altered thyroid cancers: results from the phase II LIBRETTO-321 study

Xiangqian Zheng, Qinghai Ji, Yuping Sun [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2021

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Oliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2023

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer,and RET -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

Shun Lu, Xiangqian Zheng, Yuping Sun [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2022

Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)

Shun Lu, Ying Cheng, Dingzhi Huang [...]

Therapeutic Advances in Medical Oncology

Search results